| Identification | Back Directory | [Name]
C18 Galactosylceramide-d35 (d18:1/18:0-d35) | [CAS]
145176-92-7 | [Synonyms]
C18 Galactosylceramide-d35 (d18:1/18:0-d35)
N-[(1S,2R,3E)-1-[(β-D-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecenyl]-octadecanamide-d35 | [Molecular Formula]
C42H46D35NO8 | [MOL File]
145176-92-7.mol | [Molecular Weight]
763.31 |
| Hazard Information | Back Directory | [Uses]
β-Galactosyl-C18-ceramide-d35 is deuterium labeled β-Galactosyl-C18-ceramide. β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition[1]. | [Biological Activity]
C18 Galactosylceramide-d35 is intended for use as an internal standard for the quantification of C18 galactosylceramide by GC- or LC-MS. C18 Galactosylceramide is a naturally occurring sphingolipid that has been found in the cerebellum of rats and humans.1,2 It is selectively localized with cholesterol over potassium, sodium, or phosphocholine in rat cerebellum white matter.1 [Matreya, LLC. Catalog No. 1914] | [References]
1.B?rner, K., Nygren, H., Hagenhoff, B., et al.Distribution of cholesterol and galactosylceramide in rat cerebellar white matterBiochem. Biophys. Acta.1761(3)335-344(2006)
2.Boutin, M., Sun, Y., Shacka, J.J., et al.Tandem mass spectrometry multiplex analysis of glucosylceramide and galactosylceramide isoforms in brain tissues at different stages of Parkinson DiseaseAnal. Chem.88(3)1856-1863(2016)
|
|
|